We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.94%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.49B
AUM Growth
-$764M
Cap. Flow
-$255M
Cap. Flow %
-10.24%
Top 10 Hldgs %
45.62%
Holding
96
New
13
Increased
17
Reduced
38
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$46.6M
2
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M
3
MDT icon
Medtronic
MDT
+$39.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.5M
5
EPZM
Epizyme, Inc
EPZM
+$33.5M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$50M
2
BLUE
bluebird bio
BLUE
+$36.8M
3
ELV icon
Elevance Health
ELV
+$32.6M
4
CNC icon
Centene
CNC
+$32.1M
5
NUVA
NuVasive, Inc.
NUVA
+$31.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Miscellaneous 1.72%
3 Financials 1.69%
4 Energy 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTS
26
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$35.1M 1.41%
2,269,136
+26,500
+1% +$506K
DCPH
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$34.7M 1.4%
1,653,180
+176,600
+12% +$4.34M
ELV icon
28
Elevance Health
ELV
$85.5B
$30.3M 1.22%
115,500
-118,500
-51% -$32.6M
UNH icon
29
UnitedHealth
UNH
$353B
$28.8M 1.16%
115,500
-30,320
-21% -$8.01M
OXFD
30
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$28.5M 1.14%
2,227,507
-7,900
-0.4% -$120K
TEVA icon
31
Teva Pharmaceuticals
TEVA
$42.5B
$28.2M 1.13%
+1,828,900
New +$37.5M
CVS icon
32
CVS Health
CVS
$119B
$25.1M 1.01%
382,400
-11,900
-3% -$888K
VAPO
33
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$24.9M 1%
+155,878
New +$22.5M
ANAB icon
34
AnaptysBio
ANAB
$1.67B
$23.2M 0.93%
364,050
-266,200
-42% -$19.8M
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
$23.2M 0.93%
2,948,865
-44,700
-1% -$425K
MOR
36
DELISTED
MorphoSys AG American Depositary Shares
MOR
$22.6M 0.91%
895,600
-4,300
-0.5% -$113K
REPL icon
37
Replimune Group
REPL
$1.46B
$21.9M 0.88%
2,188,957
-4,000
-0.2% -$54.1K
ICUI icon
38
ICU Medical
ICUI
$4.38B
$21M 0.84%
91,321
-90,651
-50% -$22.3M
NITE
39
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$20.7M 0.83%
1,795,846
-285,000
-14% -$3.8M
CBIO
40
Crescent Biopharma
CBIO
$659M
$18.7M 0.75%
19,785
-696
-3% -$838K
PRAH
41
DELISTED
PRA Health Sciences, Inc.
PRAH
$17.9M 0.72%
194,800
-5,200
-3% -$526K
PEN icon
42
Penumbra
PEN
$12.7B
$17.8M 0.72%
145,608
-71,521
-33% -$9.58M
HSKA
43
DELISTED
Heska Corp
HSKA
$17M 0.68%
197,713
-163,963
-45% -$16.1M
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$15.9B
$16.9M 0.68%
136,680
+135,090
+8,496% +$20M
SIBN icon
45
SI-BONE Inc
SIBN
$861M
$13.4M 0.54%
+640,900
New +$12.1M
EIDX
46
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$11.7M 0.47%
853,500
-14,200
-2% -$179K
TCDA
47
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.6M 0.47%
492,600
-2,400
-0.5% -$69K
TDOC icon
48
Teladoc Health
TDOC
$1.18B
$9.7M 0.39%
195,600
-139,100
-42% -$8.51M
LOGC
49
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$9.48M 0.38%
+911,287
New +$11M
SYRS
50
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.19M 0.37%
164,954
-660
-0.4% -$50.1K
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2018 Portfolio in Review

As of Q4 2018, Redmile Group held 96 positions worth $2.49B, down 24% from $3.25B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $255M in Q4 2018, closing 17 positions and reducing 38 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $50M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Redmile Group opened a new position in Bristol-Myers Squibb worth $44.4M.

  • Redmile Group's largest Q4 2018 buy was Bristol-Myers Squibb: 854,700 shares worth $44.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2018, an estimated $46.6M increase.
  • Redmile Group's biggest Q4 2018 reduction was Elevance Health, cutting an estimated $32.6M.
  • Redmile Group fully exited Wellcare Health Plans, Inc. in Q4 2018, selling an estimated $50M.
  • Redmile Group's ten largest holdings make up 46% of its $2.49B portfolio in Q4 2018.
  • Redmile Group opened 13 new positions and closed 17 in Q4 2018.
  • Redmile Group's portfolio value fell 24% quarter-over-quarter to $2.49B.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.